Wealth Alliance LLC Sells 35,306 Shares of Kenvue Inc. $KVUE

Wealth Alliance LLC decreased its position in Kenvue Inc. (NYSE:KVUE) by 67.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,702 shares of the company’s stock after selling 35,306 shares during the quarter. Wealth Alliance LLC’s holdings in Kenvue were worth $271,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Allianz Asset Management GmbH raised its holdings in Kenvue by 57.6% in the 2nd quarter. Allianz Asset Management GmbH now owns 45,368 shares of the company’s stock worth $950,000 after acquiring an additional 16,580 shares during the period. Forum Financial Management LP increased its stake in shares of Kenvue by 8.9% in the second quarter. Forum Financial Management LP now owns 24,943 shares of the company’s stock worth $522,000 after purchasing an additional 2,032 shares during the period. Bleakley Financial Group LLC lifted its position in shares of Kenvue by 36.0% during the 2nd quarter. Bleakley Financial Group LLC now owns 98,740 shares of the company’s stock worth $2,067,000 after purchasing an additional 26,160 shares during the last quarter. AlTi Global Inc. bought a new stake in Kenvue during the 2nd quarter valued at approximately $219,000. Finally, West Michigan Advisors LLC acquired a new stake in Kenvue in the 2nd quarter valued at approximately $264,000. 97.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of the stock in a transaction on Friday, December 12th. The shares were purchased at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the acquisition, the director directly owned 27,307,632 shares in the company, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.68% of the company’s stock.

Kenvue Stock Performance

Kenvue stock opened at $18.73 on Friday. The stock has a 50-day simple moving average of $17.54 and a 200 day simple moving average of $17.62. The stock has a market capitalization of $35.88 billion, a price-to-earnings ratio of 24.32 and a beta of 0.59. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12-month low of $14.02 and a 12-month high of $25.17.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.22 by $0.05. The business had revenue of $3.78 billion for the quarter, compared to analyst estimates of $3.68 billion. Kenvue had a net margin of 9.72% and a return on equity of 19.86%. Kenvue’s revenue was up 3.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.26 earnings per share. On average, research analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th will be paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.4%. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on KVUE shares. UBS Group increased their price objective on Kenvue from $17.00 to $19.00 and gave the company a “neutral” rating in a research report on Wednesday. Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Zacks Research upgraded Kenvue from a “strong sell” rating to a “hold” rating in a research note on Wednesday, November 26th. Evercore set a $18.00 price objective on Kenvue in a research report on Tuesday, October 28th. Finally, Citigroup lifted their price objective on Kenvue from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday. Four equities research analysts have rated the stock with a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $20.08.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.